HIF-prolyl hydroxylases and cardiovascular diseases

被引:25
|
作者
Sen Banerjee, Sucharita [1 ]
Thirunavukkarasu, Mahesh [2 ]
Rishi, Muhammad Tipu [2 ]
Sanchez, Juan A. [2 ]
Maulik, Nilanjana [2 ]
Maulik, Gautam [2 ,3 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol, Boston, MA 02115 USA
[2] Univ Connecticut, Sch Med, Dept Surg, Mol Cardiol & Angiogenesis Lab, Farmington, CT USA
[3] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA
关键词
PHD1; PHD2; PHD3; HIFs; reactive oxygen species; cardioprotection; HYPOXIA-INDUCIBLE-FACTOR; OXYGEN-DEPENDENT DEGRADATION; CENTRAL-NERVOUS-SYSTEM; FACTOR-RESPONSIVE GENE; SMOOTH-MUSCLE-CELLS; NEURAL STEM-CELLS; FACTOR-I; MYOCARDIAL-INFARCTION; 4-HYDROXYLASE INHIBITION; ISCHEMIC CARDIOMYOPATHY;
D O I
10.3109/15376516.2012.673088
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Prolyl hydroxylases belong to the family of iron- and 2-oxoglutamate-dependent dioxygenase enzyme. Several distinct prolyl hydroxylases have been identified. The hypoxia-inducible factor(HIF) prolyl hydroxylase termed prolyl hydroxylase domain(PHD) enzymes play an important role in oxygen regulation in the physiological network. There are three isoforms that have been identified: PHD1, PHD2 and PHD3. Deletion of PHD enzymes result in stabilization of HIFs and offers potential treatment options for many ischemic disorders such as peripheral arterial occlusive disease, myocardial infarction, and stroke. All three isoforms are oxygen sensors that regulate the stability of HIFs. The degradation of HIF-1 alpha is regulated by hydroxylation of the 402/504 proline residue by PHDs. Under hypoxic conditions, lack of oxygen causes hydroxylation to cease HIF-1 alpha stabilization and subsequent translocation to the nucleus where it heterodimerizes with the constitutively expressed beta subunit. Binding of the HIF-heterodimer to specific DNA sequences, named hypoxia-responsive elements, triggers the transactivation of target genes. PHD regulation of HIF-1 alpha-mediated cardioprotection has resulted in considerable interest in these molecules as potential therapeutic targets in cardiovascular and ischemic diseases. In recent years, attention has been directed towards identifying small molecule inhibitors of PHD. It is postulated that such inhibition might lead to a clinically useful strategy for protecting the myocardium against ischemia and reperfusion injury. Recently, it has been reported that the orally absorbed PHD inhibitor GSK360A can modulate HIF-1 alpha signaling and protect the failing heart following myocardial infarction. Furthermore, PHD1 deletion has been found to have beneficial effects through an increase in tolerance to hypoxia of skeletal muscle by reprogramming basal metabolism. In the mouse liver, such deletion has resulted in protection against ischemia and reperfusion. As a result of these preliminary findings, PHDs is attracting increasing interest as potential therapeutic targets in a wide range of diseases.
引用
收藏
页码:347 / 358
页数:12
相关论文
共 50 条
  • [1] Analysis of HIF-prolyl hydroxylases binding to substrates
    Landazuri, Manuel O.
    Vara-Vega, Alicia
    Viton, Mariano
    Cuevas, Yolanda
    del Peso, Luis
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 351 (02) : 313 - 320
  • [2] Role of the intracellular localization of HIF-prolyl hydroxylases
    Yasumoto, Ken-ichi
    Kowata, Yusuke
    Yoshida, Atsushi
    Torii, Satoru
    Sogawa, Kazuhiro
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2009, 1793 (05): : 792 - 797
  • [3] Determination and comparison of specific activity of the HIF-prolyl hydroxylases
    Tuckerman, JR
    Zhao, YG
    Hewitson, KS
    Tian, YM
    Pugh, CW
    Ratcliffe, PJ
    Mole, DR
    [J]. FEBS LETTERS, 2004, 576 (1-2): : 145 - 150
  • [4] Inhibition of HIF-prolyl 4-hydroxylases as a promising approach to the therapy of cardiometabolic diseases
    Aitbaev, K. A.
    Murkamilov, I. T.
    Fomin, V. V.
    [J]. TERAPEVTICHESKII ARKHIV, 2018, 90 (08): : 86 - 94
  • [5] Inhibition of HIF-prolyl hydroxylases improves healing of intestinal anastomoses
    Strowitzki, Moritz J.
    Kimmer, Gwendolyn
    Wehrmann, Julian
    Ritter, Alina S.
    Radhakrishnan, Praveen
    Opitz, Vanessa M.
    Tuffs, Christopher
    Biller, Marvin
    Kugler, Julia
    Keppler, Ulrich
    Harnoss, Jonathan M.
    Klose, Johannes
    Schmidt, Thomas
    Blanco, Alfonso
    Taylor, Cormac T.
    Schneider, Martin
    [J]. JCI INSIGHT, 2021, 6 (08)
  • [6] HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism
    Haase, Volker H.
    [J]. HEMODIALYSIS INTERNATIONAL, 2017, 21 : S110 - S124
  • [7] Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase
    Temes, E
    Martín-Puig, S
    Acosta-Iborra, B
    Castellanos, MC
    Feijoo-Cuaresma, M
    Olmos, G
    Aragonés, J
    Landazuri, MO
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (25) : 24238 - 24244
  • [8] Molecular Mechanisms of Action and Therapeutic Uses of Pharmacological Inhibitors of HIF-Prolyl 4-Hydroxylases for Treatment of Ischemic Diseases
    Selvaraju, Vaithinathan
    Parinandi, Narasimham L.
    Adluri, Ram Sudheer
    Goldman, Joshua W.
    Hussain, Naveed
    Sanchez, Juan A.
    Maulik, Nilanjana
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2014, 20 (16) : 2631 - 2665
  • [9] The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer
    Kennel, Kilian B.
    Burmeister, Julius
    Radhakrishnan, Praveen
    Giese, Nathalia A.
    Giese, Thomas
    Salfenmoser, Martin
    Gebhardt, Jasper M.
    Strowitzki, Moritz J.
    Taylor, Cormac T.
    Wielockx, Ben
    Schneider, Martin
    Harnoss, Jonathan M.
    [J]. JCI INSIGHT, 2022, 7 (22)
  • [10] HIF-Prolyl Hydroxylases in the Rat Kidney Physiologic Expression Patterns and Regulation in Acute Kidney Injury
    Schoedel, Johannes
    Klanke, Bernd
    Weidemann, Alexander
    Buchholz, Bjoern
    Bernhardt, Wanja
    Bertog, Marko
    Amann, Kerstin
    Korbmacher, Christoph
    Wiesener, Michael
    Warnecke, Christina
    Kurtz, Armin
    Eckardt, Kai-Uwe
    Willam, Carsten
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (05): : 1663 - 1674